154 related articles for article (PubMed ID: 8697006)
1. Study affirms primacy of paclitaxel-cisplatin in advanced ovarian cancer.
Am J Health Syst Pharm; 1996 Mar; 53(5):498. PubMed ID: 8697006
[No Abstract] [Full Text] [Related]
2. [First-line chemotherapy in advanced ovarian cancer].
Colombo N; Parma G; Caspani G; Donesana P; Marinetti E; Mangioni C
Tumori; 1999; 85(3 Suppl 1):S23-6. PubMed ID: 10542882
[No Abstract] [Full Text] [Related]
3. Paclitaxel as a component of initial chemotherapy of advanced ovarian cancer: is the controversy resolved.
Markman M
J Cancer Res Clin Oncol; 1998 Jan; 124(1):1-3. PubMed ID: 9498827
[No Abstract] [Full Text] [Related]
4. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
Ezcurdia L; Jovtis SL; Mickiewicz E; Temperley G; Rondinón M; Blajman C; Cóppola FS; Lewi D; Cazap E; Breier S; Fasce H; Fein L; Polera J; Triguboff E; Uranga G; Pasccón G; Luchina AM; Martínez CA; Politi PM; Rubio G; Alvarez AM
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
[TBL] [Abstract][Full Text] [Related]
6. [Choice of first-line chemotherapy for advanced ovarian cancer].
Tiuliandin SA
Vopr Onkol; 1999; 45(4):350-4. PubMed ID: 10532090
[No Abstract] [Full Text] [Related]
7. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysis.
Messori A; Trippoli S; Becagli P; Tendi E
Cancer; 1996 Dec; 78(11):2366-73. PubMed ID: 8941008
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
Young M; Plosker GL
Pharmacoeconomics; 2001; 19(12):1227-59. PubMed ID: 11772158
[TBL] [Abstract][Full Text] [Related]
9. [Ovarian cancer. The new chemotherapeutic agents].
Catimel G; Talon A
Soins; 1995 Oct; (599):20-2, 24-5. PubMed ID: 8701349
[No Abstract] [Full Text] [Related]
10. No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin.
Mesquita B; Veiga I; Pereira D; Tavares A; Pinto IM; Pinto C; Teixeira MR; Castedo S
BMC Cancer; 2005 Aug; 5():101. PubMed ID: 16095531
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacotherapy in ovarian carcinoma].
Pfisterer J; Du Bois A
MMW Fortschr Med; 2005 Oct; 147(43):34-6. PubMed ID: 16302419
[TBL] [Abstract][Full Text] [Related]
12. Platinum compounds and paclitaxel in advanced epithelial ovarian cancer.
Gadducci A; Brunetti I; Cosio S; Giannessi PG; Genazzani AR; Conte P
Anticancer Res; 1997; 17(6D):4703-8. PubMed ID: 9494592
[TBL] [Abstract][Full Text] [Related]
13. Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients.
Bruzzone M; Catsafados E; Miglietta L; Amoroso D; Pedulla F; Giannessi PG; Locatelli MC; D'Antona A; Foglia G; Mammoliti S; Turno F; Gentile A; Nicosia F; Luporini G; Ragni N; Boccardo F
Oncology; 1996; 53(5):349-53. PubMed ID: 8784466
[TBL] [Abstract][Full Text] [Related]
14. New options for the treatment of advanced ovarian cancer.
Dunton CJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel in advanced ovarian cancer: too much optimism?
Bulusu VR; Allerton R
Gynecol Oncol; 1997 Aug; 66(2):335-6. PubMed ID: 9264587
[No Abstract] [Full Text] [Related]
16. Paclitaxel and docetaxel in breast and ovarian cancer.
Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer.
McGuire W; Neugut AI; Arikian S; Doyle J; Dezii CM
J Clin Oncol; 1997 Feb; 15(2):640-5. PubMed ID: 9053488
[TBL] [Abstract][Full Text] [Related]
18. Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.
Royer B; Delroeux D; Guardiola E; Combe M; Hoizey G; Montange D; Kantelip JP; Chauffert B; Heyd B; Pivot X
Cancer Chemother Pharmacol; 2008 Mar; 61(3):415-21. PubMed ID: 17503047
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers.
Wiseman LR; Spencer CM
Drugs Aging; 1998 Apr; 12(4):305-34. PubMed ID: 9571394
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Forastiere A; Arquette M; Costa F; Heelan R; Huang Y; Kelsen DP
Cancer J; 2000; 6(5):316-23. PubMed ID: 11079171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]